Trevi Therapeutics (TRVI) Net Equity Issued and Repurchased (2019)

Trevi Therapeutics' (TRVI) quarterly Net Equity Issued and Repurchased came in at $10.0 million in Q1 2019.

Trevi Therapeutics (TRVI) Net Equity Issued and Repurchased (2019) Analysis & Trends

Trevi Therapeutics' Net Equity Issued and Repurchased history runs 1 years deep, the most recent figure standing at $10.0 million for Q1 2019.

On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $10.0 million in Q1 2019; TTM through Dec 2019 was $10.0 million, a N/A change from a year earlier, with the FY2019 full-year figure at $10.0 million, down 5.08% from the prior year.
Net Equity Issued and Repurchased steadied at $10.0 million in Q1 2019 per TRVI's latest filing.
Across five years, Net Equity Issued and Repurchased topped out at $10.0 million in Q1 2019 and bottomed at $10.0 million in Q1 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	163.10 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	141.90 Mn
10	Trevi Therapeutics	2.50 Bn	2.50 Bn	-	-

Download Data

Date	Value
Mar 31, 2019	9.96 Mn
Mar 31, 2019	9.96 Mn